191 related articles for article (PubMed ID: 32875515)
41. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
Latham S; Bartley PA; Budgen B; Ross DM; Hughes E; Branford S; White D; Hughes TP; Morley AA
J Clin Pathol; 2016 Sep; 69(9):817-21. PubMed ID: 26837312
[TBL] [Abstract][Full Text] [Related]
42. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns.
López-Jorge CE; Gómez-Casares MT; Jiménez-Velasco A; García-Bello MA; Barrios M; Lopez J; de la Iglesia S; Ramírez T; Sánchez G; Heiniger AI; Molero T
Ann Hematol; 2012 Aug; 91(8):1245-50. PubMed ID: 22526369
[TBL] [Abstract][Full Text] [Related]
43. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Neumann F; Herold C; Hildebrandt B; Kobbe G; Aivado M; Rong A; Free M; Rössig R; Fenk R; Schneider P; Gattermann N; Royer-Pokora B; Haas R; Kronenwett R
Eur J Haematol; 2003 Jan; 70(1):1-10. PubMed ID: 12631253
[TBL] [Abstract][Full Text] [Related]
44. Digital PCR can provide improved
Smitalova D; Dvorakova D; Racil Z; Romzova M
Pract Lab Med; 2021 May; 25():e00210. PubMed ID: 33778144
[No Abstract] [Full Text] [Related]
45. MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.
Claudiani S; Gatenby A; Szydlo R; Nesr G; Abulafia AS; Palanicawandar R; Nteliopoulos G; Khorashad J; Foroni L; Apperley JF; Milojkovic D
Haematologica; 2019 Nov; 104(11):2206-2214. PubMed ID: 30923102
[TBL] [Abstract][Full Text] [Related]
46. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
Scott S; Cartwright A; Francis S; Whitby L; Sanzone AP; Mulder A; Galimberti S; Dulucq S; Mauté C; Lauricella C; Salmon M; Rose S; Willoughby J; Boeckx N; Pallisgaard N; Maier J; Leibundgut EO; Zizkova H; Ling Goh L; Duong C; Tang WF; Ma E; Shivakumar Y; Beppu L; Bhagavatula P; Chantry A
Br J Haematol; 2021 Jul; 194(1):53-60. PubMed ID: 34114218
[TBL] [Abstract][Full Text] [Related]
47.
Lee SE; Choi SY; Kim SH; Song HY; Yoo HL; Lee MY; Kang KH; Hwang HJ; Jang EJ; Kim DW
Korean J Intern Med; 2017 Jan; 32(1):125-136. PubMed ID: 27334764
[TBL] [Abstract][Full Text] [Related]
48. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer.
Campomenosi P; Gini E; Noonan DM; Poli A; D'Antona P; Rotolo N; Dominioni L; Imperatori A
BMC Biotechnol; 2016 Aug; 16(1):60. PubMed ID: 27538962
[TBL] [Abstract][Full Text] [Related]
49. The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.
Spiess B; Naumann N; Galuschek N; Rinaldetti S; Kossak-Roth U; Tarnopolscaia I; Felde E; Fabarius A; Hofmann WK; Saußele S; Seifarth W
PLoS One; 2018; 13(4):e0196326. PubMed ID: 29689094
[TBL] [Abstract][Full Text] [Related]
50. Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
Jacobs K; Moerman A; Vandepoele K; Abeele TVD; De Mulder K; Steel E; Clauwaert M; Louagie H
Int J Lab Hematol; 2024 Jun; ():. PubMed ID: 38840510
[TBL] [Abstract][Full Text] [Related]
51. Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population.
Kuan JW; Su AT; Sim SP; Tay SP
BMC Cancer; 2024 Jun; 24(1):734. PubMed ID: 38877512
[TBL] [Abstract][Full Text] [Related]
52. [Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
Larripa I; Ruiz MS; Gutiérrez M; Bianchini M
Medicina (B Aires); 2017; 77(1):61-72. PubMed ID: 28140313
[TBL] [Abstract][Full Text] [Related]
53. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
54. Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.
Foskett P; Gerrard G; Foroni L
Methods Mol Biol; 2014; 1160():115-24. PubMed ID: 24740226
[TBL] [Abstract][Full Text] [Related]
55. Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene.
Kuan JW; Su AT; Leong CF; Osato M; Sashida G
Acta Haematol; 2020; 143(2):96-111. PubMed ID: 31401626
[TBL] [Abstract][Full Text] [Related]
56. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
[TBL] [Abstract][Full Text] [Related]
57. Identification of rare atypical BCR-ABL1 transcript: A case report.
Saha J; Gopinath V; Nair CK; Roshan D
Indian J Pathol Microbiol; 2023; 66(3):624-626. PubMed ID: 37530356
[TBL] [Abstract][Full Text] [Related]
58. Molecular monitoring in CML and the prospects for treatment-free remissions.
Deininger MW
Hematology Am Soc Hematol Educ Program; 2015; 2015():257-63. PubMed ID: 26637731
[TBL] [Abstract][Full Text] [Related]
59. External quality assessment of p210 BCR-ABL1 transcript quantification by RT-qPCR: Findings and recommendations.
Fu Y; Zhang R; Wu Q; Zhang J; Bao L; Li J
Int J Lab Hematol; 2019 Feb; 41(1):46-54. PubMed ID: 30203581
[TBL] [Abstract][Full Text] [Related]
60. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
